Features of screening and diagnosis of renal cell carcinoma in kidney transplant recipients

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The most effective method of treating patients with end stage renal disease is donor kidney transplantation. However, recipients of this group have an increased risk of developing malignant neoplasms, including renal cell carcinoma (RCC), which can be localized both in the recipient’s own kidneys and in the kidney transplant. Despite the development of transplantology, there is still heterogeneity in clinical recommendations for screening recipients for RCC, especially for the transplanted kidney. Also, the latest methods for diagnosing RCC, actively used in the population of non-transplanted patients, have been poorly studied in relation to kidney transplant tumors.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Ruslan Trushkin

City Clinical Hospital No. 52 of the Moscow Healthcare Department; Peoples’ Friendship University of Russia named after Patrice Lumumba

Хат алмасуға жауапты Автор.
Email: uro52@mail.ru
ORCID iD: 0000-0002-3108-0539

Dr.Sci. (Med.), Head of the Urology Department; Department of Urology and Operative Nephrology with a Course in Oncourology

Ресей, Moscow; Moscow

Teymur Isaev

City Clinical Hospital No. 52 of the Moscow Healthcare Department

Email: dr.isaev@mail.ru
ORCID iD: 0000-0003-3462-8616

Dr.Sci. (Med.), Head of the Urology Department

Ресей, Moscow

Aleksandr Sokolov

Central Clinical Hospital with a Polyclinic of the Administrative Directorate of the President of the Russian Federation

Email: salexdoc@gmail.com
ORCID iD: 0009-0007-0302-0428
SPIN-код: 5887-1880

Cand.Sci. (Med.), Urologist

Ресей, Moscow

Sergey Sokolov

City Clinical Hospital No. 52 of the Moscow Healthcare Department

Email: sergey.sokolow28@mail.ru
ORCID iD: 0009-0004-7016-2360

Urologist, Urology Department

Ресей, Moscow

Sergey Andreev

City Clinical Hospital No. 52 of the Moscow Healthcare Department

Email: uro52@mail.ru
ORCID iD: 0000-0002-9147-4636

Head of the Clinical Pharmacology Department

Ресей, Moscow

Tuong Ho

Peoples’ Friendship University of Russia named after Patrice Lumumba

Email: uro52@mail.ru
ORCID iD: 0000-0003-2873-9053

Postgraduate Student, Department of Urology and Operative Nephrology with a Course in Oncourology

Ресей, Москва

Әдебиет тізімі

  1. Ying T., Shi B., Kelly P.J. et al. Death after kidney transplantation: an analysis by era and time post-transplant. J. Am. Soc. Nephrol. 2020;31:2887–99.
  2. Musquera M., Sierra A., Diekmann F. et al. Increasing kidney grafts for transplantation. World J. Urol. 2021;39(7):2795–800.
  3. Warren H., Olsburgh J. Management of Renal Cell Carcinoma and Other Renal Masses in the Kidney Graft. Сurr. Urol. Rep. 2020;21(1):8.
  4. Åkerlund J., Holmberg E., Lindblad P. et al. Increased risk for renal cell carcinoma in end stage renal disease – a population-based case-control study. Scand. J. Urol. 2021;55(3):209–14.
  5. Wang I.-K., Yu T.-M., Yen T.-H. et al. Comparison of the risks of renal cell carcinoma or urothelial cancer between hemodialysis and peritoneal dialysis patients. Int. Urol. Nephrol. 2023;55(9):2267–74.
  6. Cheung C.Y., Tang S.C.W. Oncology in nephrology comes of age: A focus on chronic dialysis patients. Nephrology (Carlton). 2019;24(4):380–6.
  7. Cheung C.Y., Chan G.C.W., Chan S.K. et al. Cancer incidence and mortality in Chronic dialysis population: A multicenter cohort study. Am. J. Nephrol. 2016;43:153–59.
  8. Vajdic C.M., McDonald S.P., McCredie M.R.E. et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823–31.
  9. Lin H.F., Li Y.H., Wang C.H. et al. Increased risk of cancer in chronic dialysis patients: A population-based cohort study in Taiwan. Nephrol. Dial. Transplant. 2012;27:1585–90.
  10. Hortlund M., Arroyo Mühr L.S., Storm H. et al. Cancer risks after solid organ transplantation and after long-term dialysis. Int. J. Cancer. 2017;140:1091–101.
  11. Chien C.C., Han M.M., Chiu Y.H. et al. Epidemiology of cancer in end-stage renal disease dialysis patients: A national cohort study in Taiwan. J. Cancer. 2017;8:9–18.
  12. Sarasin F.P., Wong J.B., Levey A.S., Meyer K.B. Screening for acquired cystic kidney disease: A decision analytic perspective. Kidney Int. 1995;48:207–19.
  13. Grantham J.J. Acquired cystic kidney disease. Kidney Int. 1991;40:143–52.
  14. Kyllo R.L., Tanagho Y.S., Kaouk J.H. et al. Prospective multi-center study of oncologic outcomes of robot-assisted partial nephrectomy for pT1 renal cell carcinoma. BMC. Urol. 2012;12:11.
  15. Su M.Z., Campbell N.A., Lau H.M. et al. Management of renal masses in transplant allografts at an Australian kidney-pancreas transplant unit. Transplantation. 2014;97(6):654–9.
  16. Sprangers B., Nair V., Launay-Vacher V. et al. Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin. Kidney J. 2018;11(3):315–29.
  17. Katabathina V.S., Menias C.O., Tammisetti V.S. et al. Malignancy after solid organ transplantation: comprehensive imaging review. Radiographics. 2016;36(5):10–1.
  18. González-López R., Bueno-Serrano G., Mayor-De Castro J. et al. Clinical presentation of renal cell carcinoma in renal transplant. Arch. Esp. Urol. 2009;62(3):207–13.
  19. Kiss G., Korda D., Szabó G. et al. Oncological Screening of Kidney Transplant Patients: The Role of Ultrasound Examination. Transplant. Proc. 2019;51(4):1231–3.
  20. Kiss G., Székely B., Farkas Á.Z. et al. Oncological Screening of Kidney Tumors After Renal Transplantation. Transplant. Proc. 2022;54(9):2589–92.
  21. Vaudreuil L., Bessede T., Boissier R. et al. De novo renal carcinoma arising in non-functional kidney graft: a national retrospective study. Int. Urol. Nephrol. 2020;52(7):1235–41.
  22. Moon A., Rogers A., Talbot D., Rix D. Renal Cell Cancer in a European Regional Renal Transplant Population: Is There a Role for Immediate Native Renal Radiological Surveillance Before and After Transplantation? Тransplant. Proc. 2015;47(6):1840–4.
  23. Diana P., Klatte T., Amparore D. et al. Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group. World J. Urol. 2023;41(4): 929–40.
  24. Putz J., Kestel V., Herout R. et al. Urogenital tumors following kidney transplantation-monocentric analysis of incidences and overview of urological preventive measures. Urologie. 2024.
  25. Fabio C., Riccardo A., Ithaar D. et al. Management of renal cell carcinoma in transplant kidney: a systematic review and meta-analysis. Minerva Urol. Nephrol. 2023;75(1):1–16.
  26. Yeh C.-C., Khan A., Muo C.-H. et al. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan. Exp. Clin. Transplant. 2020;18(2):224–33.
  27. Turshudzhyan A. Post-renal transplant malignancies: Opportunities for prevention and early screening. Cancer Treat Res. Commun. 2021;26:100.
  28. Shirazian S., Starakiewicz P., Latcha S. Cancer Screening in End-Stage Kidney Disease. Adv. Chron. Kidney Dis. 2021;28(5):502–8.
  29. Chewcharat A., Thongprayoon C., Bathini T. et al. Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis. J. Clin. Med. 2019;8(4):530.
  30. Griffith J.J., Amin K.A., Waingankar N. et al. Solid Renal Masses in Transplanted Allograft Kidneys: A Closer Look at the Epidemiology and Management. Am. J. Transplant. 2017;17:2775–81.
  31. Vegso G., Toronyi E., Deak P.A. et al. Detection and management of renal cell carcinoma in the renal allograft. Int. Urol. Nephrol. 2013; 45:93–8.
  32. Leveridge M., Musquera M., Evans E. et al. Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients. J. Urol. 2011;186:219–23.
  33. Rouprêt M., Peraldi M.N., Thaunat O., et al. Renal cell carcinoma of the grafted kidney: how to improve screening and graft tracking. Transplantation. 2004;77:146–8.
  34. Zakrocka I., Pachowicz M., Baranowicz-Gąszczyk I. et al. Renal cell carcinoma in a kidney transplant recipient: rare clinical manifestations. Pol. Arch. Intern. Med. 2020;130(5):449–51.
  35. Walto T.J., McCulloch T.A., Bishop M.C. Aggressive renal cell carcinoma in a 27-year-old kidney transplant. Nephrol. Dial. Transplant. 2005;20:1018–9.
  36. Penn I. Cancers in renal transplant recipients. Adv. Ren. Replace Ther. 2000;7(2):147–56.
  37. Белавина Н.И., Трушкин Р.Н., Иванова Е.С. и др. Опыт применения контраст-усиленного ультразвукового исследования у пациента с успешно прооперированной злокачественной опухолью почечного трансплантата. Наблюдение из практики и краткий обзор литературы. Нефрология и диализ. 2021;23(3):414–24. [Belavina N.I., Trushkin R.N., Ivanova E.S. and others. The experience of using contrast-enhanced ultrasound in a patient with a successfully operated malignant tumor of a kidney transplant. Practical observations and a brief review of the literature. Nephrology and dialysis. 2021;23(3):414–24 (In Russ.)].
  38. Quaia E., Bertolotto M., Cioffi V. et al. Comparison of contrastenhanced sonography with unenhanced sonography and contrast-enhanced CT in the diagnosis of malignancy in complex cystic renal masses. AJR. Am. J. Roentgenol. 2008;191(4):1239–49.
  39. Finley D.S., Beck S., Box G. et al. Percutaneous and laparoscopic cryoablation of small renal masses. J. Urol. 2008;180:492–8.
  40. Yu Z., Hu M., Li Z. et al. Anti-G250 nanobody-functionalized nanobubbles targeting renal cell carcinoma cells for ultrasound molecular imaging. Nanotechnology. 2020;31(20):205–10.
  41. Silvestri T., Stacul F., Bertolotto M. et al. Percutaneous cryoablation of a renal cell carcinoma in a transplanted kidney. Can. J. Urol. 2014;21(4): 7390–2.
  42. Aron M., Hegarty N.J., Remer E. et al. Percutaneous radiofrequency ablation of tumor in transplanted kidney. Urology. 2007;69:57–78.
  43. García Álvarez T., Mazuecos Blanca A., Navas García N. et al. Early diagnosis and treatment of renal cell carcinoma of native kidney in kidney transplantation. Nefrologia. 2011;31(5):567–72.
  44. Yohannan B., Sridhar A., Kaur H. et al. Screening for renal cell carcinoma in renal transplant recipients: a single-centre retrospective study. BMJ. Open. 2023;13(9).
  45. Villanueva L.A.A., Knust M., Quintella L. et al. Renal oncocytoma in a kidney transplant patient: the imaging features on contrast-enhanced ultrasonography (CEUS): a case report. J. Bras. Nefrol. 2018;40(1):86–90.
  46. Vogel C., Ziegelmüller B., Ljungberg B. et al. Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Clin. Genitourin. Cancer. 2019;17(2):345–55.
  47. Kazmierski B.J., Sharbidre K.G., Robbin M.L., Grant E.G. Contrast-Enhanced Ultrasound for the Evaluation of Renal Transplants. J. Ultrasound. Med. 2020;39(12):2457–68.
  48. Sun M., Wang C., Jiang F. et al. Diagnostic value and clinical significance of ultrasound combined with CT in cystic renal cell carcinoma review of the literature. Oncol. Lett. 2019;18(2):1395–401.
  49. Favi E., Raison N., Ambrogi F. et al. Systematic review of ablative therapy for the treatment of renal allograft neoplasms. World J. Clin. Cases. 2019;7(17):2487–504.
  50. Zhang F., Lu Z., Wang F. et al. Advances in the pathogenesis and prevention of contrast-induced nephropathy. Life Sci. 2020;259:118–21.
  51. Nash K., Hafeez A., Hou S. Hospital-acquired renal insufficiency. Am. J. Kidney Dis. 2002;39(5):930–36.
  52. Toso A., Leoncini M., Maioli M. et al. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention). Randomized Controlled Trial. JACC. Cardiovasc. Interv. 2014;7(12): 1421–29.
  53. Cheungpasitporn W., Thongprayoon C., Mao M.A. et al. Contrast-induced acute kidney injury in kidney transplant recipients: A systematic review and meta-analysis. World J. Transplant. 2017;7:81–87.
  54. Wentland A.L, Yamashita R., Kino A. et al. Differentiation of benign from malignant solid renal lesions using CT-based radiomics and machine learning: comparison with radiologist interpretation. Abdom. Radiol. (NY). 2023;48(2):642–48.
  55. Bhandari A., Ibrahim M., Sharma C. et al. CT-based radiomics for differentiating renal tumours: a systematic review. Abdom. Radiol. (NY). 2021;46(5):2052–63.
  56. Massa'a R.N., Stoeckl E.M., Lubner M.G. et al. Differentiation of benign from malignant solid renal lesions with MRI-based radiomics and machine learning. Abdom. Radiol. (NY). 2022;47(8):2896–904.
  57. Li Y., Wang Y., Qin J., et al. Meta-analysis of diffusion-weighted imaging in the differential diagnosis of renal lesions. Clin. Imaging. 2018;52:264–72.
  58. Campi R., Pecoraro A., Serni S. 'Case of the Month' from the Specialist Centre for Kidney Cancer, Royal Free London Hospital, UK: 99mTc-sestamibi SPECT-CT to Differentiate Renal Cell Carcinoma from Benign Oncocytoma: The promise of value-oriented, cost-effective, shared decision-making for patients with localized renal masses: new imaging tools for a new diagnostic work-up. Eur. Urol. 2022;82(4):443–44.
  59. Gorin M.A., Rowe S.P., Baras A.S. et al. Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. Eur. Urol. 2016;69(3): 413–16.
  60. Lindenberg L., Mena E., Choyke P.L. et al. PET imaging in renal cancer. Curr. Opin. Oncol. 2019;31(3):216–21.
  61. Chambad eD., Meria P., Tariel E. et al. Nephron sparing surgery is a feasible and efficient treatment of T1a renal cell carcinoma in kidney transplant: a prospective series from a single center. J. Urol. 2008;180: 2106–09.
  62. Cachoeira E.T., Teixeira da Silva A.G., Fernandes A.S. et al. Primary desmoid tumor in renal transplant graft site: first case report. Urol. Case Rep. 2018;23:44–45.
  63. Guleryuz K., Doerfler A., Codas R. et al.; Renal Transplantation Committee of the French Urological Association (CTAFU). A national study of kidney graft tumor treatments: toward ablative therapy. Surgery. 2016;160:237–44.
  64. Dao M., Pécriaux A., Bessede T. et al. BK virus-associated collecting duct carcinoma of the renal allograft in a kidney-pancreas allograft recipient. Oncotarget. 2018;9:15157–63.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу